Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.79) by 35.77 percent. This is a 71.67 percent increase over losses of $(1.80) per share from the same period last year. The company reported quarterly sales of $5.092 million which beat the analyst consensus estimate of $4.525 million by 12.53 percent. This is a 1.38K percent increase over sales of $344.000 thousand the same period last year.